Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-121 Phase 1 Crossover Study in Autism
NCT04944901Phase 1Completed
- Sponsor
- Scioto Biosciences, Inc.
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Implantable Devices, Yeast Strains, Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing SB-121 Sequence with Placebo Sequence (2 arms). Primary endpoints: Adverse Event of Special Interest (AESIs) and Adverse Events (AEs) Leading to Discontinuation at 98 days, Sephadex Microspheres in the Stool at Day 35 and 1 more. Started Aug 2021; status: completed.
02
Drugs
SB-121
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04944901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944901.